Fluicell makes progress in early development of advanced therapy medicinal products for diabetes based on Biopixlar
Today, Fluicell announces that the company has made important progress in the early development work regarding a medicinal product based on Biopixlar-generated tissues. The product development is focused on the treatment of type 1 diabetes with transplantable biocomposites and is the result of extensive research and development work carried out internally by Fluicell. The company intends to present the results at international science meetings and in one or more scientific publications.
In type 1 diabetes, the body’s own immune system breaks down insulin-producing beta cells in the pancreas. Fluicell’s research team, led by CSO Dr. Tatsiana Lobovkina, has, using Biopixlar’s unique technology for high-resolution 3D bioprinting, succeeded in creating transferrable biocomposites that mimic the insulin-producing function of the pancreas. The company has now observed insulin release from these biocomposites as a function of glucose stimulation, a very important indicator of tissue functionality and a prerequisite for developing a future therapy against type 1 diabetes. The company believes that these results have provided important technological and biomedical evidence for the concept, which will be developed further towards the preclinical phase. Fluicell also conducts exploratory development work of transplantable biocomposites targeting heart failure (caused by tissue damage) as well as eye diseases, such as age-related macular degeneration.
CSO Dr. Tatsiana Lobovkina comments:
“We have obtained very promising results in our development of insulin-producing biocomposites that harness Biopixlar’s strength to create detailed biological tissues with programmable function and I want to thank the entire R&D team for their great work. With Biopixlar, we can choose one or more cell types, including insulin-producing beta cells, and have control over their location and the histology of the resulting tissue. This is of crucial importance when it comes to both the function and longevity of the transplantable biomomposite. We see great potential in creating new tissue-based products for the treatment of diabetes as we move forward in the development work.”